Teleterápia versus teleterápia és boost brachyterápia a nyelvgyökrák sugárkezelé sében

5 éves eredmények

Translated title of the contribution: Teletherapy versus teletherapy and "boost" brachytherapy in the treatment of base of tongue tumors: 5-year results

Nagy Z. Takácsi, Oberna Ferenc, A. Somogyi, C. Polgár, T. Major, Pólus Károly, J. Fodor, Németh György

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Aim: To study the importance of high-dose-rate (HDR) boost brachytherapy (BT) after percutaneous irradiation of base of tongue tumors. Methods: Between 1992 and 2000 seventy patients with biopsy proven carcinoma of the base of tongue were treated with primary radiation therapy. Fourty patients received a mean dose of 61 Gy (range, 50-72 Gy) external beam irradiation, and afterwards 30 patients were treated with a mean dose of 18 Gy (range, 12-30 Gy) boost HDR BT. Prognostic factors were analyzed in uni-and multivariate model. Results: At a median follow-up of 56 (16-108) months, boost BT increased the incidence of local tumor control (LTC) from 38% to 67% (p=0.0145). The 5-year probability of LTC was 60% vs. 36% (p=0.0188), the locoregional tumor control 52% vs. 34% (p=0.0753) and the overall survival (OS) 46% vs. 26% (p=0.0545), respectively, in favor of the boost group. Serious, grade 4 radiation toxicity occurred in 5% (2/40) and 13% (4/30) without or with boost treatment, respectively (p=0.2110). In multivariate analyses for LTC, tumor size (p=0.0042) and boost (p=0.0444), and for OS tumor size (p=0.0047) and nodal status (p=0.0163) had a significant effect. Conclusion: Boost BT after teletherapy improves LTC significantly without considerable increase in the risk of side-effects.

Original languageHungarian
Pages (from-to)297-301
Number of pages5
JournalMagyar Onkologia
Volume48
Issue number4
Publication statusPublished - 2004

Fingerprint

Brachytherapy
Tongue
Neoplasms
Therapeutics
Survival
Radiotherapy
Multivariate Analysis
Radiation
Carcinoma
Biopsy
Incidence

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Teleterápia versus teleterápia és boost brachyterápia a nyelvgyökrák sugárkezelé sében : 5 éves eredmények. / Takácsi, Nagy Z.; Ferenc, Oberna; Somogyi, A.; Polgár, C.; Major, T.; Károly, Pólus; Fodor, J.; György, Németh.

In: Magyar Onkologia, Vol. 48, No. 4, 2004, p. 297-301.

Research output: Contribution to journalArticle

@article{e828197669244a988dba10b75709fca7,
title = "Teleter{\'a}pia versus teleter{\'a}pia {\'e}s boost brachyter{\'a}pia a nyelvgy{\"o}kr{\'a}k sug{\'a}rkezel{\'e} s{\'e}ben: 5 {\'e}ves eredm{\'e}nyek",
abstract = "Aim: To study the importance of high-dose-rate (HDR) boost brachytherapy (BT) after percutaneous irradiation of base of tongue tumors. Methods: Between 1992 and 2000 seventy patients with biopsy proven carcinoma of the base of tongue were treated with primary radiation therapy. Fourty patients received a mean dose of 61 Gy (range, 50-72 Gy) external beam irradiation, and afterwards 30 patients were treated with a mean dose of 18 Gy (range, 12-30 Gy) boost HDR BT. Prognostic factors were analyzed in uni-and multivariate model. Results: At a median follow-up of 56 (16-108) months, boost BT increased the incidence of local tumor control (LTC) from 38{\%} to 67{\%} (p=0.0145). The 5-year probability of LTC was 60{\%} vs. 36{\%} (p=0.0188), the locoregional tumor control 52{\%} vs. 34{\%} (p=0.0753) and the overall survival (OS) 46{\%} vs. 26{\%} (p=0.0545), respectively, in favor of the boost group. Serious, grade 4 radiation toxicity occurred in 5{\%} (2/40) and 13{\%} (4/30) without or with boost treatment, respectively (p=0.2110). In multivariate analyses for LTC, tumor size (p=0.0042) and boost (p=0.0444), and for OS tumor size (p=0.0047) and nodal status (p=0.0163) had a significant effect. Conclusion: Boost BT after teletherapy improves LTC significantly without considerable increase in the risk of side-effects.",
author = "Tak{\'a}csi, {Nagy Z.} and Oberna Ferenc and A. Somogyi and C. Polg{\'a}r and T. Major and P{\'o}lus K{\'a}roly and J. Fodor and N{\'e}meth Gy{\"o}rgy",
year = "2004",
language = "Hungarian",
volume = "48",
pages = "297--301",
journal = "Magyar Onkologia",
issn = "0025-0244",
publisher = "Akademiai Kiado",
number = "4",

}

TY - JOUR

T1 - Teleterápia versus teleterápia és boost brachyterápia a nyelvgyökrák sugárkezelé sében

T2 - 5 éves eredmények

AU - Takácsi, Nagy Z.

AU - Ferenc, Oberna

AU - Somogyi, A.

AU - Polgár, C.

AU - Major, T.

AU - Károly, Pólus

AU - Fodor, J.

AU - György, Németh

PY - 2004

Y1 - 2004

N2 - Aim: To study the importance of high-dose-rate (HDR) boost brachytherapy (BT) after percutaneous irradiation of base of tongue tumors. Methods: Between 1992 and 2000 seventy patients with biopsy proven carcinoma of the base of tongue were treated with primary radiation therapy. Fourty patients received a mean dose of 61 Gy (range, 50-72 Gy) external beam irradiation, and afterwards 30 patients were treated with a mean dose of 18 Gy (range, 12-30 Gy) boost HDR BT. Prognostic factors were analyzed in uni-and multivariate model. Results: At a median follow-up of 56 (16-108) months, boost BT increased the incidence of local tumor control (LTC) from 38% to 67% (p=0.0145). The 5-year probability of LTC was 60% vs. 36% (p=0.0188), the locoregional tumor control 52% vs. 34% (p=0.0753) and the overall survival (OS) 46% vs. 26% (p=0.0545), respectively, in favor of the boost group. Serious, grade 4 radiation toxicity occurred in 5% (2/40) and 13% (4/30) without or with boost treatment, respectively (p=0.2110). In multivariate analyses for LTC, tumor size (p=0.0042) and boost (p=0.0444), and for OS tumor size (p=0.0047) and nodal status (p=0.0163) had a significant effect. Conclusion: Boost BT after teletherapy improves LTC significantly without considerable increase in the risk of side-effects.

AB - Aim: To study the importance of high-dose-rate (HDR) boost brachytherapy (BT) after percutaneous irradiation of base of tongue tumors. Methods: Between 1992 and 2000 seventy patients with biopsy proven carcinoma of the base of tongue were treated with primary radiation therapy. Fourty patients received a mean dose of 61 Gy (range, 50-72 Gy) external beam irradiation, and afterwards 30 patients were treated with a mean dose of 18 Gy (range, 12-30 Gy) boost HDR BT. Prognostic factors were analyzed in uni-and multivariate model. Results: At a median follow-up of 56 (16-108) months, boost BT increased the incidence of local tumor control (LTC) from 38% to 67% (p=0.0145). The 5-year probability of LTC was 60% vs. 36% (p=0.0188), the locoregional tumor control 52% vs. 34% (p=0.0753) and the overall survival (OS) 46% vs. 26% (p=0.0545), respectively, in favor of the boost group. Serious, grade 4 radiation toxicity occurred in 5% (2/40) and 13% (4/30) without or with boost treatment, respectively (p=0.2110). In multivariate analyses for LTC, tumor size (p=0.0042) and boost (p=0.0444), and for OS tumor size (p=0.0047) and nodal status (p=0.0163) had a significant effect. Conclusion: Boost BT after teletherapy improves LTC significantly without considerable increase in the risk of side-effects.

UR - http://www.scopus.com/inward/record.url?scp=15744395892&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=15744395892&partnerID=8YFLogxK

M3 - Article

VL - 48

SP - 297

EP - 301

JO - Magyar Onkologia

JF - Magyar Onkologia

SN - 0025-0244

IS - 4

ER -